Literature DB >> 11454806

Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant.

F P Vleggaar1, H R van Buuren, P E Zondervan, F J ten Kate, W C Hop.   

Abstract

The clinical and pathological findings of four females with primary biliary cirrhosis (PBC) with an unusual and hitherto not well recognised course are reported. Patients suffered severe pruritus and weight loss with progressive icteric cholestasis which did not respond to such treatments as ursodeoxycholic acid and immunosuppressives. In all cases liver histology revealed marked bile duct loss without however significant fibrosis or cirrhosis. Further diagnostic studies and repeat biopsies confirmed the absence of liver cirrhosis as well as other potential causes of hyperbilirubinaemia. Comparison of the fibrosis-ductopenia relationship for our cases with that for a group of 101 non-cirrhotic PBC patients indicated that in the former the severity of bile duct loss relative to the amount of fibrosis was significantly higher. The proportion of portal triads containing an interlobular bile duct was 3%, 4%, 6%, and 10% compared with 45% (median; range 8.3--100%) for controls (p<0.001). Three patients received a liver transplant 6--7 years after the first manifestation of PBC because of progressive cholestasis, refractory pruritus, and weight loss, while the fourth patient is considering this option. In one case cirrhosis had developed at the time of transplantation while the others still had non-cirrhotic disease. These cases suggest that cholestatic jaundice in non-cirrhotic PBC may be secondary to extensive "premature" or accelerated intrahepatic bile duct loss. Although the extent of fibrosis may be limited initially, progression to cirrhosis appears to be inevitable in the long run. Despite intact protein synthesis and absence of cirrhotic complications, liver transplantation in the pre-cirrhotic stage for preventing malnutrition and to improve quality of life should be considered for these patients.

Entities:  

Mesh:

Year:  2001        PMID: 11454806      PMCID: PMC1728410          DOI: 10.1136/gut.49.2.276

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

Review 1.  Vanishing bile duct disorders.

Authors:  V J Desmet
Journal:  Prog Liver Dis       Date:  1992

Review 2.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

3.  Early cirrhosis--or primary cholangitis?

Authors:  S W Schalm; H R van Buuren
Journal:  Lancet       Date:  1997-01-25       Impact factor: 79.321

Review 4.  Vanishing bile duct syndrome in drug-induced liver disease.

Authors:  V J Desmet
Journal:  J Hepatol       Date:  1997       Impact factor: 25.083

5.  [Hemolytic anemia as cause of a marked bilirubin increase in primary biliary cirrhosis].

Authors:  M A Mahl; J von Schönfeld; M Uppenkamp; N Breuer
Journal:  Dtsch Med Wochenschr       Date:  1996-10-04       Impact factor: 0.628

6.  Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease.

Authors:  O M Crosbie; J P Crown; N P Nolan; R Murray; J E Hegarty
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

Review 7.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

8.  Chronic cholestasis in a young man.

Authors:  J Ludwig; C B Rosen; K D Lindor; J H Helzberg; K R Watson
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

9.  Idiopathic biliary ductopenia in adults without symptoms of liver disease.

Authors:  A Moreno; V Carreño; A Cano; C González
Journal:  N Engl J Med       Date:  1997-03-20       Impact factor: 91.245

10.  Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.

Authors:  S G Hubscher; M A Lumley; E Elias
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

View more
  10 in total

1.  A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients.

Authors:  Tatsuo Inamine; Minoru Nakamura; Ayumi Kawauchi; Yayoi Shirakawa; Hisae Hashiguchi; Yoshihiro Aiba; Akinobu Taketomi; Ken Shirabe; Makoto Nakamuta; Shigeki Hayashi; Takeo Saoshiro; Atsumasa Komori; Hiroshi Yatsuhashi; Shinji Kondo; Katsuhisa Omagari; Yoshihiko Maehara; Hiromi Ishibashi; Kazuhiro Tsukamoto
Journal:  J Gastroenterol       Date:  2010-12-01       Impact factor: 7.527

Review 2.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

3.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

4.  Acute hepatitis E unmasking primary biliary cholangitis and Takayasu aortoarteritis in a patient.

Authors:  Ramesh Kumar; Ruchika Narayan
Journal:  Med J Armed Forces India       Date:  2019-12-16

5.  Fatigue in chronic cholestasis.

Authors:  P Milkiewicz; E J Heathcote
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

6.  Treatment of autoimmune liver disease: current and future therapeutic options.

Authors:  Palak J Trivedi; Gideon M Hirschfield
Journal:  Ther Adv Chronic Dis       Date:  2013-05       Impact factor: 5.091

Review 7.  Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies.

Authors:  Malgorzata Milkiewicz; Llorenç Caballería; Daniel S Smyk; Piotr Milkiewicz
Journal:  Auto Immun Highlights       Date:  2012-10-16

8.  Paracrine cellular senescence exacerbates biliary injury and impairs regeneration.

Authors:  Sofia Ferreira-Gonzalez; Wei-Yu Lu; Alexander Raven; Benjamin Dwyer; Tak Yung Man; Eoghan O'Duibhir; Philip J Starkey Lewis; Lara Campana; Tim J Kendall; Thomas G Bird; Nuria Tarrats; Juan-Carlos Acosta; Luke Boulter; Stuart J Forbes
Journal:  Nat Commun       Date:  2018-03-09       Impact factor: 14.919

Review 9.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

10.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.